Ann: Results of Major Clinical Study-Genera Biosy, page-8

re: Ann: Results of Major Clinical Study-Gene... Liqcrisis

I agree that the false negative rates for HC2 appear anomolous for an approved screening assay and that the PapType figures at 5.5% (CIN 3) and 8.9% (CIN2+) are too high.

My guess with a screening population would be that both HC2 and PapType false neagtives will drop substantially compared to this study.

It appears that these particular samples were ASCUS smears with an extroadinarily high disease prevalence rate. IMO this may have had a significant impact on the skew re the false negatives.

However a head to head trial of HC2 with samples run against histology is what it is and the data on face value is good.

I look forward to seeing more clinical data generated later in the year.